Allo BMT in Advanced Leukemia or High Grade Lymphoma

Stanford University

Status: Completed

Conditions: Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin; Leukemia; Lymphoma, Non-Hodgkin

Treatments: Procedure: ablative allogeneic hematopoietic cell transplantation

Study type: Interventional

Funder types: Other

Identifiers

NCT00186290

BMT34

74165

NCT00186290

Details and patient eligibility

About

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Full description

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Enrollment: 145 estimated patients

Sex: All

Ages: Under 50 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:HLA identical donor

• adequate organ function
• other life threatening disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)